Fibrolamellar Carcinoma News and Research

RSS
Study reveals overactive PKA protein as driver of fibrolamellar carcinoma

Study reveals overactive PKA protein as driver of fibrolamellar carcinoma

Cells use liquid droplets to regulate signaling pathways, study finds

Cells use liquid droplets to regulate signaling pathways, study finds

Immune cell protein identified as potential target for rare liver cancer treatment

Immune cell protein identified as potential target for rare liver cancer treatment

Organoid models provide new scientific insights into a rare childhood liver cancer

Organoid models provide new scientific insights into a rare childhood liver cancer

Gift boosts efforts to understand and combat rare cancers

Gift boosts efforts to understand and combat rare cancers

New grant to Harvard Medical School is boosting efforts to understand and combat rare cancers

New grant to Harvard Medical School is boosting efforts to understand and combat rare cancers

Researchers pinpoint treatment target for rare liver cancer in adolescents, young adults

Researchers pinpoint treatment target for rare liver cancer in adolescents, young adults

CASI reports financial results for second quarter 2015

CASI reports financial results for second quarter 2015

CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar carcinoma patients

CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar carcinoma patients

CASI Pharmaceuticals reports net loss of $1.8 million for first quarter 2015

CASI Pharmaceuticals reports net loss of $1.8 million for first quarter 2015

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

CASI's ENMD-2076 gets FDA Orphan Drug designation for HCC treatment

CASI's ENMD-2076 gets FDA Orphan Drug designation for HCC treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.